Tazeen Ahmad
Stock Analyst at B of A Securities
(2.39)
# 2,338
Out of 4,829 analysts
200
Total ratings
42.28%
Success rate
-2.16%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | $41 → $23 | $17.30 | +32.95% | 7 | May 9, 2025 | |
| PTCT PTC Therapeutics | Upgrades: Buy | $55 → $68 | $44.23 | +53.74% | 17 | May 9, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $63 → $68 | $57.38 | +18.51% | 8 | Apr 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $302 → $325 | $251.15 | +29.40% | 3 | Mar 21, 2025 | |
| STRO Sutro Biopharma | Downgrades: Underperform | $11 → $1 | $0.87 | +14.74% | 2 | Mar 14, 2025 | |
| ARVN Arvinas | Maintains: Buy | $54 → $28 | $6.61 | +323.60% | 2 | Mar 12, 2025 | |
| MRUS Merus | Maintains: Buy | $73 → $70 | $40.90 | +71.15% | 5 | Mar 10, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $42 → $40 | $3.08 | +1,198.70% | 4 | Mar 10, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $30 → $28 | $14.37 | +94.85% | 2 | Mar 10, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $184 → $179 | $115.71 | +54.70% | 3 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $22 | $7.43 | +196.10% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $11.90 | +84.95% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.50 | +100.67% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $68 → $90 | $58.98 | +52.59% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $5.99 | +150.63% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $6 | $6.57 | -8.68% | 14 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $191 | $151.46 | +26.11% | 8 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $150 | $92.87 | +61.52% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $5.36 | -62.69% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $549.27 | +10.51% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $166 → $213 | $36.27 | +487.26% | 21 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $35.11 | +116.46% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $22 | $17.44 | +26.15% | 13 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $1.15 | +1,117.39% | 2 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $1.60 | +525.00% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.04 | +476.92% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $7.06 | +112.46% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $16.60 | -33.73% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $9.97 | +0.30% | 11 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $1.27 | +57.48% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $0.80 | +648.04% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $8.35 | +79.64% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $38.35 | +56.45% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.07 | +1,395.33% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $7.71 | +458.08% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $163.02 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $9.83 | +2,951.88% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $0.62 | +1,351.61% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $25.12 | +91.08% | 6 | Oct 10, 2018 |
Apellis Pharmaceuticals
May 9, 2025
Downgrades: Neutral
Price Target: $41 → $23
Current: $17.30
Upside: +32.95%
PTC Therapeutics
May 9, 2025
Upgrades: Buy
Price Target: $55 → $68
Current: $44.23
Upside: +53.74%
Rhythm Pharmaceuticals
Apr 10, 2025
Maintains: Buy
Price Target: $63 → $68
Current: $57.38
Upside: +18.51%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $302 → $325
Current: $251.15
Upside: +29.40%
Sutro Biopharma
Mar 14, 2025
Downgrades: Underperform
Price Target: $11 → $1
Current: $0.87
Upside: +14.74%
Arvinas
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $6.61
Upside: +323.60%
Merus
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $40.90
Upside: +71.15%
4D Molecular Therapeutics
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $3.08
Upside: +1,198.70%
Denali Therapeutics
Mar 10, 2025
Maintains: Buy
Price Target: $30 → $28
Current: $14.37
Upside: +94.85%
Neurocrine Biosciences
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $115.71
Upside: +54.70%
Dec 19, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $7.43
Upside: +196.10%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $11.90
Upside: +84.95%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.50
Upside: +100.67%
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $58.98
Upside: +52.59%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $5.99
Upside: +150.63%
Oct 9, 2024
Maintains: Underperform
Price Target: $11 → $6
Current: $6.57
Upside: -8.68%
Sep 23, 2024
Maintains: Buy
Price Target: $175 → $191
Current: $151.46
Upside: +26.11%
Sep 16, 2024
Maintains: Buy
Price Target: $125 → $150
Current: $92.87
Upside: +61.52%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $5.36
Upside: -62.69%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $549.27
Upside: +10.51%
Jun 21, 2024
Maintains: Buy
Price Target: $166 → $213
Current: $36.27
Upside: +487.26%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $35.11
Upside: +116.46%
May 10, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $17.44
Upside: +26.15%
Apr 9, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $1.15
Upside: +1,117.39%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $1.60
Upside: +525.00%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.04
Upside: +476.92%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $7.06
Upside: +112.46%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $16.60
Upside: -33.73%
Jul 13, 2023
Upgrades: Buy
Price Target: $10
Current: $9.97
Upside: +0.30%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $1.27
Upside: +57.48%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $0.80
Upside: +648.04%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $8.35
Upside: +79.64%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $38.35
Upside: +56.45%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.07
Upside: +1,395.33%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $7.71
Upside: +458.08%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $163.02
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $9.83
Upside: +2,951.88%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $0.62
Upside: +1,351.61%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $25.12
Upside: +91.08%